Johnson & Johnson is cutting its profit expectations for the year as the coronavirus disrupts economies worldwide.
Medical procedures, hospital and doctor visits in particular have been upended by the outbreak and Johnson & Johnson is the first major U.S. drug and medical supply company to post quarterly earnings.
The New Brunswick, New Jersey, company reported a first-quarter profit of $5.8 billion, or $2.17 per share. Adjusted per-share earnings were $2.30, far exceeding projections of $2.03 from Wall Street analysts, according to a survey by Zacks Investment Research.
Revenue was $20.69 billion, also beating expectations.
Johnson & Johnson expects adjusted full-year earnings in the range of $7.50 to $7.90 per share. That's down from the $8.95 to $9.10 previously projected.
It expects revenue of $77.5 billion to $80.5 billion.
Shares are up 3% before the opening bell Tuesday.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
